uhm....sorry but, no. They do clearly state in their analysis that the $0.90 target essentially based on a 8.5 times multiple (low such a company/industry) of 2026 anticipated earnings.....
"Our fair value of 90c per share puts Orthocell on 8.5x EV/Revenue in FY26. This is broadly inline with where Vericel (7.4x) and Straumann (8.9x) trade one year forward and a significant discount to Polynovo on 18x and Mesoblast on 52x. It is also important to note that early-stage competitors Embody and Biorez were recently acquired for EV/Revenue multiples of 92 and 104x respectively"
That is essentially on probability DCF of Remplir/Striate and excludes ATI and ACI which are call option style possibilities of partnership, along with takeover possibility as they discuss.
Veritas 0.90c valuation, page-4
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $74.31M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 36.5¢ | 35.5¢ | $65.26K | 181.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 56760 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 5000 | 1 |
View Market Depth
| Last trade - 15.04pm 28/06/2024 (20 minute delay) ? |
| OCC (ASX) Chart |